Sun W, et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate [published online ahead of print, 2020 Nov 21]. EBioMedicine. 2020;62:103132. doi:10.1016/j.ebiom.2020.103132 米マウントサイナイ医科大学
Udwadia ZF, et al. Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial. Int J Infect Dis. 2020;S1201-9712(20)32453-X. doi:10.1016/j.ijid.2020.11.142
Chen H, et al. First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients. Medicine (Baltimore). 2020;99(48):e23357. doi:10.1097/MD.0000000000023357
C型肝炎ウイルスプロテアーゼ阻害薬ダノプレビル+リトナビルの対COVID-19オープンラベル試験
最初のウイルス陰転まで中央値2日(1~8日)
治療開始後4~12日で被検者11人全員退院
Wang Y, et al. Investigation of the Potential Mechanism Governing the Effect of the Shen Zhu San on COVID-19 by Network Pharmacology. Evid Based Complement Alternat Med. 2020;2020:8468303. doi:10.1155/2020/8468303
Shen Zhu San (参术散?= 熟地黄、白芍、当归、川芎、人参、白术、半夏、陈皮、甘草) のネットワーク薬理学
Samuel RM, et al. Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men. Cell Stem Cell. 2020;S1934-5909(20)30547-6. doi:10.1016/j.stem.2020.11.009
Iesa MA, et al. SARS-COV2 and P. falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt. New Microbes New Infect. 2020;100817. doi:10.1016/j.nmni.2020.100817
Murakami S, et al. Detection and Characterization of Bat Sarbecovirus Phylogenetically Related to SARS-CoV-2, Japan. Emerg Infect Dis. 2020;26(12):3025-3029. doi:10.3201/eid2612.203386
Pormohammad A, et al. Zinc and SARS‑CoV‑2: A molecular modeling study of Zn interactions with RNA‑dependent RNA‑polymerase and 3C‑like proteinase enzymes. Int J Mol Med. 2020;10.3892/ijmm.2020.4790. doi:10.3892/ijmm.2020.4790
Desterke C, et al. Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID-19-associated organ failure. Stem Cells Transl Med. 2020;10.1002/sctm.20-0189. doi:10.1002/sctm.20-0189
骨髄・脂肪組織・臍帯由来間葉系幹細胞ではACE2が強く発現している
胎盤由来間葉系幹細胞・ヒトES細胞、ヒトiPS細胞ではACE2の発現は非常に低いレベル
11/20アップデートで紹介した論文の結果と一致しない
Avanzini MA, et al. Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. Stem Cells Transl Med. 2020;10.1002/sctm.20-0385. doi:10.1002/sctm.20-0385